✦ LIBER ✦

Definitive radiation therapy for medically inoperable patients with stage I and II non-small cell lung cancer

✍ Scribed by Kazushige Hayakawa; Norio Mitsuhashi; Yoshihiro Saito; Yuko Nakayama; Susumu Katano; Masaya Furuta; Hideyuki Sakurai; Takeo Takahashi; Hideo Niibe

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 528 KB
Volume: 4
Category: Article
ISSN: 1065-7541
DOI: 10.1002/(sici)1520-6823(1996)4:4<165::aid-roi3>3.0.co;2-w

No coin nor oath required. For personal study only.

✦ Synopsis

The treatment results of 84 patients with clinical stage I and II non-small cell lung cancer (NSCLC) treated with definitive radiation therapy (RT) alone at Gunma University Hospital from 1976 through 1989 were retrospectively analyzed. All patients were treated with 10 M V X-rays using anteroposterior parallel opposed fields. The total dose ranged from 60 to 80 Gy, except for one patient given 90 Gy with once-daily standard fractionation. The 2-and 5-year survival rates were 74% and 31% for 28 patients with stage I disease, compared with 40% and 19% for 56 patients with stage 11, respectively (P < 0.05). Fifty-three patients with tumors less than 5 cm in diameter had an in-field progression rate of 14% a t 2 years, in comparison with 38% of 31 patients with tumors greater than 5 cm (P < 0.05). The difference of survival rates for these two groups was statistically significant (P < 0.005). Ten patients given a total dose of 80 Gy or over had only 17% local progression at the time of last follow-up, however, they had not been alive beyond 3 years because they developed pulmonary insufficiency due to severe stenosis of the proximal bronchus. A multivariate analysis indicated primary tumor size as the only significant prognostic factor for survival. In conclusion, the tumor size was the most important factor not only for local control but also for distant failure. It was also suggested that the optimal radiation dose for medically inoperable stage 1-11 NSCLC ranged from 60 to 70 Gy with once-daily standard fractionation. Radiat Oncol Invest 1996;4:16&170.

📜 SIMILAR VOLUMES

Radiotherapy for patients with medically

Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma : Smaller volumes and higher doses-A review

✍ Gregory S. Sibley 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## Background: Surgical resection remains the treatment of choice for patients with stage i nonsmall cell lung carcinoma. however, there is a group of patients who are medically inoperable and are treated with radiotherapy alone. this review summarizes findings from published series of radiotherapy

Hyperfractionated radiation therapy with

Hyperfractionated radiation therapy with and without concurrent chemotherapy for advanced non–small cell lung cancer

✍ Branislav Jeremic; Stanisa Jevremovic; Ljiljana Mijatovic; Slobodan Milisavljevi 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 478 KB 👁 2 views

Clinical stage II non-small cell lung ca

Clinical stage II non-small cell lung cancer treated with radiation therapy alone:The significance of clinically staged ipsilateral hilar adenopathy (N1 disease)

✍ Seth A. Rosenthal; Walter J. Curran Jr.; Scoff H. Herbert; Edward N. Hughes; How 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 687 KB

Background. The prognosis of patients with clinically staged hilar nodal involvement (Stage N1) or clinical Stage I1 non-small cell lung cancer (NSCLC, Stage T1-2NlMO) treated with radiation therapy (RT) alone is not well established. Methods. Records of 758 patients with clinical Stage 1-111 NSCLC

Thoracic radiation therapy improves the

Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis

✍ Hui Zhu; Zongmei Zhou; Yan Wang; Nan Bi; Qinfu Feng; Junling Li; Jima Lv; Dongfu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB 👁 1 views

## BACKGROUND: The authors conducted a retrospective study to evaluate the effects of thoracic radiation therapy (TRT) for patients with extensive-stage small cell lung cancer (ED-SCLC). METHODS: Between January 2003 and December 2006, the records of 119 patients who were diagnosed with ED-SCLC (a

Reduced survival in patients with stage-

Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors

✍ Rafael Rosell; Alex Pifarré; Mariano Monzó; Julio Astudillo; M. Paz López-Cabrer 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 88 KB 👁 2 views

To better understand whether replication-error-type instability (RER 1 ) is a frequent genetic alteration event in surgicalpathologic stage-I non-small-cell lung cancer (NSCLC) and identify whether it constitutes an independent prognostic parameter, we examined 35 surgical-pathologic stage-I-NSCLC p

Phase II study of neoadjuvant chemothera

Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer

✍ Margaret Deutsch; Jeffrey Crawford; Kenneth Leopold; Walter Wolfe; William Foste 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 939 KB